The Centers for Disease Control (CDC)/Health Resources and Services Administration (HRSA) Advisory Committee on HIV, Viral Hepatitis and STD Prevention and Treatment Notice of Charter Renewal, 72868 [2012-29471]

Download as PDF 72868 Federal Register / Vol. 77, No. 235 / Thursday, December 6, 2012 / Notices Kimberly S. Lane, Deputy Director, Office of Scientific Integrity, Office of the Associate Director for Science, Office of the Director, Centers for Disease Control and Prevention. [FR Doc. 2012–29474 Filed 12–5–12; 8:45 am] DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention The Centers for Disease Control (CDC)/ Health Resources and Services Administration (HRSA) Advisory Committee on HIV, Viral Hepatitis and STD Prevention and Treatment Notice of Charter Renewal This gives notice under the Federal Advisory Committee Act (Pub. L. 92– 463) of October 6, 1972, that the CDC/ HRSA Advisory Committee on HIV, Viral Hepatitis and STD Prevention and Treatment, Department of Health and Human Services, has been renewed for a 2-year period through November 25, 2014. Contact Person for More Information: Kevin Fenton, M.D., Ph.D., Designated Federal Officer, CDC/HRSA Advisory Committee on HIV, Viral Hepatitis and STD Prevention and Treatment, Department of Health and Human Services, CDC, 1600 Clifton Road, NE., Mailstop E07, Atlanta, Georgia 30333, telephone (404) 639–8000 or fax (404) 639–8600. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Dated: November 29, 2012. Elaine L. Baker, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. BILLING CODE 4163–18–P Centers for Disease Control and Prevention Request for Nominations for Candidates To Serve on the National Public Health Surveillance and Biosurveillance Advisory Committee (NPHSBAC) BILLING CODE 4163–18–P [FR Doc. 2012–29471 Filed 12–5–12; 8:45 am] DEPARTMENT OF HEALTH AND HUMAN SERVICES Correction: This notice was published in the Federal Register on November 1, 2012 Volume 77, Number 215, page 66620. This notice is to announce the extension of submission for potential nominees. Nominations should be sent, in writing, and postmarked by December 21, 2012: Vernellia Johnson, Management and Program Analyst, Public Health Surveillance and Informatics Program Office, Centers for Disease Control and Prevention, Office of Surveillance, Epidemiology and Laboratory Services Century, 1600 Clifton Road NE., MS E–97, Atlanta, GA 30333 or via email to hft9@cdc.gov. Telephone and facsimile submissions cannot be accepted. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities for both CDC and the Agency for Toxic Substances and Disease Registry. Dated: November 30, 2012. Cathy Ramadei, Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC). [FR Doc. 2012–29478 Filed 12–5–12; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2012–D–1086] Compliance Guidance for Small Business Entities on Labeling and Effectiveness Testing; Sunscreen Drug Products for Over-the-Counter Human Use; Notice of Availability AGENCY: Food and Drug Administration, HHS. mstockstill on DSK4VPTVN1PROD with ACTION: Notice. The Food and Drug Administration (FDA) is announcing the availability of a compliance guidance for small business entities entitled ‘‘Labeling and Effectiveness Testing: SUMMARY: VerDate Mar<15>2010 16:42 Dec 05, 2012 Jkt 229001 PO 00000 Frm 00056 Fmt 4703 Sfmt 4703 Sunscreen Drug Products for Over-theCounter Human Use; Small Entity Compliance Guide.’’ This guidance is intended to help small businesses understand and comply with the requirements of the final rule addressing labeling and effectiveness testing requirements for over-the counter (OTC) sunscreen drug products. The guidance describes the requirements of the final rule in plain language and provides answers to common questions on how to comply with the rule. This guidance was prepared in accordance with the Small Business Regulatory Enforcement Fairness Act. DATES: Submit either electronic or written comments on Agency guidances at any time. ADDRESSES: Submit written requests for single copies of this guidance to the Division of Drug Information, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 2201, Silver Spring, MD 20993–0002. Send one self-addressed adhesive label to assist that office in processing your requests. See the SUPPLEMENTARY INFORMATION section for electronic access to the guidance document. Submit electronic comments on the guidance to https://www.regulations.gov. Submit written comments to the Division of Dockets Management (HFA– 305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. FOR FURTHER INFORMATION CONTACT: Reynold Tan, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 22, Rm. 5493, Silver Spring, MD 20993–0002, 301– 796–1009. SUPPLEMENTARY INFORMATION: I. Background FDA is announcing the availability of a compliance guidance for small business entities entitled ‘‘Labeling and Effectiveness Testing: Sunscreen Drug Products for Over-the-Counter Human Use; Small Entity Compliance Guide.’’ This guidance summarizes the June 17, 2011, final rule (76 FR 35620) regarding labeling and testing requirements for OTC sunscreen drug products. Under the 2011 sunscreen final rule, required and permitted labeling is based upon the results of effectiveness testing. The effectiveness testing consists of a sun protection factor (SPF) Test and a Broad Spectrum (ultraviolet A (UVA) and ultraviolet B (UVB) protection) Test. In addition, a test demonstrating water resistance that accompanies the SPF Test to ensure retention of SPF E:\FR\FM\06DEN1.SGM 06DEN1

Agencies

[Federal Register Volume 77, Number 235 (Thursday, December 6, 2012)]
[Notices]
[Page 72868]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-29471]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


The Centers for Disease Control (CDC)/Health Resources and 
Services Administration (HRSA) Advisory Committee on HIV, Viral 
Hepatitis and STD Prevention and Treatment Notice of Charter Renewal

    This gives notice under the Federal Advisory Committee Act (Pub. L. 
92-463) of October 6, 1972, that the CDC/HRSA Advisory Committee on 
HIV, Viral Hepatitis and STD Prevention and Treatment, Department of 
Health and Human Services, has been renewed for a 2-year period through 
November 25, 2014.
    Contact Person for More Information: Kevin Fenton, M.D., Ph.D., 
Designated Federal Officer, CDC/HRSA Advisory Committee on HIV, Viral 
Hepatitis and STD Prevention and Treatment, Department of Health and 
Human Services, CDC, 1600 Clifton Road, NE., Mailstop E07, Atlanta, 
Georgia 30333, telephone (404) 639-8000 or fax (404) 639-8600.
    The Director, Management Analysis and Services Office, has been 
delegated the authority to sign Federal Register notices pertaining to 
announcements of meetings and other committee management activities, 
for both the Centers for Disease Control and Prevention and the Agency 
for Toxic Substances and Disease Registry.

    Dated: November 29, 2012.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease 
Control and Prevention.
[FR Doc. 2012-29471 Filed 12-5-12; 8:45 am]
BILLING CODE 4163-18-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.